ID26964A - Komposisi dan metode untuk pengaturan pengaktifan limfosit - Google Patents

Komposisi dan metode untuk pengaturan pengaktifan limfosit

Info

Publication number
ID26964A
ID26964A IDW20001845A ID20001845A ID26964A ID 26964 A ID26964 A ID 26964A ID W20001845 A IDW20001845 A ID W20001845A ID 20001845 A ID20001845 A ID 20001845A ID 26964 A ID26964 A ID 26964A
Authority
ID
Indonesia
Prior art keywords
limfosit
activities
composition
setting
methods
Prior art date
Application number
IDW20001845A
Other languages
English (en)
Inventor
Jeffrey A Ledbetter
Martha Hayden Ledbetter
William A Brady
Laura S Grosmaire
Che-Leung Law
Raj Dua
Original Assignee
Xcyte Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xcyte Therapies Inc filed Critical Xcyte Therapies Inc
Publication of ID26964A publication Critical patent/ID26964A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IDW20001845A 1998-02-19 1999-02-18 Komposisi dan metode untuk pengaturan pengaktifan limfosit ID26964A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7527498P 1998-02-19 1998-02-19
US10868398P 1998-11-16 1998-11-16

Publications (1)

Publication Number Publication Date
ID26964A true ID26964A (id) 2001-02-22

Family

ID=26756645

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20001845A ID26964A (id) 1998-02-19 1999-02-18 Komposisi dan metode untuk pengaturan pengaktifan limfosit

Country Status (14)

Country Link
US (3) US20020155604A1 (id)
EP (1) EP1469883A2 (id)
JP (1) JP2003525016A (id)
KR (1) KR20010034512A (id)
CN (1) CN1316910A (id)
AU (1) AU3295299A (id)
BR (1) BR9907950A (id)
CA (1) CA2321199A1 (id)
HK (1) HK1041210A1 (id)
ID (1) ID26964A (id)
IL (1) IL137963A0 (id)
NO (1) NO20004095L (id)
NZ (1) NZ506453A (id)
WO (1) WO1999042077A2 (id)

Families Citing this family (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1637160A3 (en) 1999-05-07 2006-05-03 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
WO2002057445A1 (en) 2000-05-26 2002-07-25 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
WO2001090190A2 (en) 2000-05-26 2001-11-29 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
ATE513854T1 (de) * 2000-12-13 2011-07-15 Bac Ip B V Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
JP4524074B2 (ja) 2001-03-09 2010-08-11 アーナソン， バリー ジー． 低親和性Ｆｃγレセプターを標的化する重合体の免疫グロブリン融合タンパク質
US8163289B2 (en) 2001-03-09 2012-04-24 Iterative Therapeutics, Inc. Methods and compositions involving polymeric immunoglobulin fusion proteins
GB0110029D0 (en) * 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
WO2003025020A1 (en) * 2001-09-13 2003-03-27 Institute For Antibodies Co., Ltd. Method of constructing camel antibody library
ES2321701T3 (es) * 2001-10-12 2009-06-10 Schering Corporation Uso de anticuerpos biespecificos que se unen al receptor de activacion fcepsilonri y al receptor de inhibicion ox2ra (cd200ra) para regular respuestas inmunes.
JP2005289809A (ja) * 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
US20090217404A1 (en) * 2002-09-27 2009-08-27 Lowe Scott W Cell-based RNA interference and related methods and compositions
EP1599573B1 (en) * 2003-02-17 2013-06-19 Cold Spring Harbor Laboratory Model for studying the role of genes in tumor resistance to chemotherapy
US20090186839A1 (en) * 2003-02-17 2009-07-23 Cold Spring Harbor Laboratory Model for studying the role of genes in chemoresistance
DK1623017T3 (da) * 2003-05-08 2011-01-10 Life Technologies Corp Frembringelse og isolering af antigenspecifikke T-celler
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
AU2004263538B2 (en) * 2003-08-08 2009-09-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US20050118173A1 (en) * 2003-09-22 2005-06-02 Xcyte Therapies, Inc. Compositions and methods to accelerate hematologic recovery
WO2005049085A1 (en) * 2003-11-18 2005-06-02 Valeocyte Therapies Llc Use of soluble complexes to facilitate cell activation
WO2005075515A2 (en) * 2004-02-06 2005-08-18 Unilever N.V. Immunoglobulins and method for their modification
ATE540973T1 (de) 2004-07-22 2012-01-15 Five Prime Therapeutics Inc Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung
FR2879605B1 (fr) * 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
US8137907B2 (en) * 2005-01-03 2012-03-20 Cold Spring Harbor Laboratory Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
CN105535967B (zh) * 2005-02-15 2022-05-03 杜克大学 抗cd19抗体及其在肿瘤学中的应用
US8444973B2 (en) * 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
EP1885755A4 (en) * 2005-05-05 2009-07-29 Univ Duke CD19 ANTIBODY THERAPY FOR AUTOIMMUNE DISEASES
ES2379283T3 (es) 2005-05-18 2012-04-24 Ablynx N.V. Proteínas de unión a albúmina sérica
PL2444424T3 (pl) 2005-05-20 2019-01-31 Ablynx N.V. Ulepszone Nanociała TM do leczenia zaburzeń, w których pośredniczy agregacja
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
EP1896587A2 (en) * 2005-05-31 2008-03-12 Cold Spring Harbor Laboratory METHODS FOR PRODUCING MICRORNAs
EP1904101A4 (en) * 2005-06-08 2011-06-15 Univ Duke ANTI-CD19 ANTIBODY THERAPY FOR TRANSPLANTATION
SG155912A1 (en) 2005-07-25 2009-10-29 Trubion Pharmaceuticals Inc B-cell reduction using cd37-specific and cd20-specific binding molecules
AU2007257692B2 (en) 2006-06-12 2013-11-14 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
CN103694349A (zh) 2006-09-08 2014-04-02 米迪缪尼有限公司 人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用
EP2102244A2 (en) 2006-12-19 2009-09-23 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
EP2557090A3 (en) 2006-12-19 2013-05-29 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
WO2009068627A2 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
EP2947097A1 (en) 2008-04-07 2015-11-25 Ablynx N.V. Amino acid sequences directed against the Notch pathways and uses thereof
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
EP2313436B1 (en) 2008-07-22 2014-11-26 Ablynx N.V. Amino acid sequences directed against multitarget scavenger receptors and polypeptides
EA024877B1 (ru) 2008-10-02 2016-10-31 Эмерджент Продакт Дивелопмент Сиэтл, Ллс Связывающие множество мишеней белки, обладающие антагонистическими свойствами по отношению к cd86
KR101470690B1 (ko) 2009-04-10 2014-12-10 아블린쓰 엔.브이. Ｉｌ－６ｒ에 대한 개선된 아미노산 서열 및 ｉｌ－６ｒ 관련 질환 및 질병의 치료를 위한 그를 포함하는 폴리펩티드
CN102459332B (zh) 2009-06-05 2015-08-19 埃博灵克斯股份有限公司 用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体
CA2780753A1 (en) * 2009-11-14 2011-05-19 Kuang-Yuh Chyu Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2011073180A1 (en) 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
WO2011098518A2 (en) 2010-02-11 2011-08-18 Ablynx Nv Delivery of immunoglobulin variable domains and constructs thereof
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
EP2571901B1 (en) 2010-05-20 2019-01-02 Ablynx N.V. Biological materials related to her3
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
TWI619730B (zh) 2010-11-08 2018-04-01 Ablynx Nv 趨化細胞素受體結合多肽
US20140088019A1 (en) 2011-02-11 2014-03-27 Zyngenia, Inc. Monovalent and Multivalent Multispecific Complexes and Uses Thereof
EP2691418A1 (en) 2011-03-28 2014-02-05 Ablynx N.V. Bispecific anti-cxcr7 immunoglobulin single variable domains
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
IN2014CN00437A (id) 2011-06-23 2015-04-03 Ablynx Nv
US20150158934A1 (en) 2011-09-09 2015-06-11 Ucl Business Plc Broadly neutralizing vhh against hiv-1
EP3311837A1 (en) 2011-09-23 2018-04-25 Ablynx NV Prolonged inhibition of interleukin-6 mediated signaling
AU2012316859A1 (en) 2011-09-29 2014-04-17 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
EP2747783B1 (en) 2011-09-30 2017-06-14 Ablynx N.V. Biological materials related to c-met
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
AU2013208364B2 (en) 2012-01-13 2017-10-26 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
US20160075766A1 (en) 2013-05-21 2016-03-17 Roche Diagnostics Operations, Inc. Method for producing antibodies using ovine b-cells and uses thereof
SG11201609162SA (en) 2014-05-16 2016-12-29 Ablynx Nv Improved immunoglobulin variable domains
KR20250099289A (ko) 2014-05-16 2025-07-01 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
JP6568207B2 (ja) * 2014-05-19 2019-08-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ヒツジｂ細胞を用いて抗体を産生するための方法およびその使用
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
RU2016151645A (ru) 2014-07-01 2018-08-03 Пфайзер Инк. Биспецифические гетеродимерные диантитела и их применение
JP2017538779A (ja) 2014-10-10 2017-12-28 アブリンクス・エヌ・フェー Ｒｓｖ感染の治療方法
HUE044199T2 (hu) 2014-10-10 2019-10-28 Ablynx Nv Inhalációs készülék légúti betegségek aeroszolos terápiájában való alkalmazásra
JP6862343B2 (ja) 2014-12-19 2021-04-21 アブリンクス エン．ヴェー． システイン結合ナノボディダイマー
US10273305B2 (en) 2015-04-02 2019-04-30 Ablynx N.V. Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity
CN107708720A (zh) 2015-04-06 2018-02-16 苏伯多曼有限责任公司 含有从头结合结构域的多肽及其用途
JP7163028B2 (ja) 2015-05-13 2022-10-31 アブリンクス エン．ヴェー． Ｃｄ３反応性に基づくｔ細胞リクルートポリペプチド
HRP20250651T1 (hr) 2015-05-13 2025-07-18 Ablynx Nv Polipeptidi koji regrutiraju t stanice koji se temelje na tcr alfa/beta reaktivnosti
EP3352760B1 (en) 2015-09-21 2026-03-11 Aptevo Research and Development LLC Cd3 binding polypeptides
US20190062706A1 (en) * 2015-10-28 2019-02-28 Life Technologies As Selective expansion of different subpopulations of t cells by the alteration of cell surfacing signals and signal ratio
NO2768984T3 (id) 2015-11-12 2018-06-09
JP7256011B2 (ja) 2015-11-27 2023-04-11 アブリンクス エン．ヴェー． Ｃｄ４０ｌを阻害するポリペプチド
CN109196360A (zh) * 2016-03-15 2019-01-11 奈克斯根尼亚公司 细胞表面分子结合性刺激响应性聚合物组合物和方法
WO2017167714A1 (en) 2016-03-30 2017-10-05 F. Hoffmann-La Roche Ag B-cell cultivation method
US20190127447A1 (en) 2016-05-02 2019-05-02 Ablynx N.V. Treatment of rsv infection
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
BR112019010061A2 (pt) 2016-11-16 2019-08-13 Ablynx Nv polipeptídeos de recrutamento de células t capazes de se ligarem ao cd123 e tcr alfa/beta
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
CN108264561B (zh) * 2016-12-30 2021-09-10 惠和生物技术(上海)有限公司 一种结合cd19、cd3和t细胞负共刺激分子的三功能分子及其应用
WO2018122147A1 (en) 2017-01-02 2018-07-05 F. Hoffmann-La Roche Ag B-cell cultivation method
US11891451B2 (en) 2017-05-11 2024-02-06 Vib Vzw Glycosylation of variable immunoglobulin domains
JP6978516B2 (ja) 2017-05-19 2021-12-08 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 胸腺細胞上清を産生するための方法
KR20250011229A (ko) 2017-06-02 2025-01-21 메르크 파텐트 게엠베하 Adamts 결합성 면역글로불린
MX2019014504A (es) 2017-06-02 2020-07-20 Merck Patent Gmbh Inmunoglobulinas de union a agrecano.
CA3064318A1 (en) 2017-06-02 2018-12-06 Merck Patent Gmbh Polypeptides binding adamts5, mmp13 and aggrecan
EP4678235A2 (en) 2017-06-02 2026-01-14 Merck Patent GmbH Mmp13 binding immunoglobulins
MX2020004933A (es) 2017-11-14 2021-01-08 Arcellx Inc Polipéptidos que contienen dominios d y sus usos.
EP3717632B1 (en) 2017-11-30 2022-10-26 F. Hoffmann-La Roche AG B-cell cultivation method
US12037382B2 (en) 2018-02-05 2024-07-16 Stichting Vu Inverse agonistic anti-US28 antibodies
WO2019156566A1 (en) 2018-02-12 2019-08-15 Umc Utrecht Holding B.V. Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
AR114269A1 (es) 2018-02-26 2020-08-12 Ablynx Nv Secuencias nucleotídicas mejoradas que codifican para péptidos de unión
MX2020011023A (es) 2018-04-19 2021-01-29 Baylor College Medicine Reprogramación de células t cd4 en células cd8 citotóxicas por expresión forzada de cd8ab y receptores de células t restringidos de clase 1.
WO2019226050A2 (en) 2018-05-24 2019-11-28 Wageningen Universiteit Novel viral anti-infective reagents
EP3636657A1 (en) 2018-10-08 2020-04-15 Ablynx N.V. Chromatography-free antibody purification method
WO2020080941A1 (en) 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
WO2020130838A2 (en) 2018-12-21 2020-06-25 Qvq Holding B.V. Antibodies for preventing or treating candidiasis
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
JP2022541697A (ja) * 2019-02-27 2022-09-27 ジャージャン ナノマブ テクノロジー センター カンパニー リミテッド 高解像度で広範なエピトープを網羅するために、ラクダ科動物抗体を生成する配列ベースのハイスループット法
JP7592621B2 (ja) 2019-04-02 2024-12-02 イミュネチューン・ベー・フェー 免疫刺激組成物及びその使用
WO2020245663A1 (en) 2019-06-01 2020-12-10 Institut Pasteur Nanobody-based ns1 assay for the specific diagnosis of acute zika virus infection
WO2021025556A1 (en) 2019-08-05 2021-02-11 Stichting Vu Identification and elimination of hcmv-infected cells
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
KR20230166150A (ko) 2020-08-19 2023-12-06 젠코어 인코포레이티드 항-cd28 조성물
KR20230122084A (ko) 2020-12-18 2023-08-22 아블린쓰 엔.브이. Tcr 알파/베타 반응성에 기초한 t 세포 동원 폴리펩타이드
US12234473B2 (en) 2020-12-31 2025-02-25 Immatics US, Inc. CD8 polypeptides, compositions, and methods of using thereof
US20240228593A9 (en) 2021-02-19 2024-07-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services SINGLE DOMAIN ANTIBODIES THAT NEUTRALIZE SARS-CoV-2
WO2022216157A1 (en) 2021-04-09 2022-10-13 Stichting Radboud Universiteit Off the shelf proximity biotinylation enzyme
WO2022258606A1 (en) 2021-06-07 2022-12-15 Gadeta B.V. Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
EP4381094B1 (en) 2021-08-03 2025-07-02 Wageningen Universiteit Argonaute-based nucleic acid detection system
JP2025508827A (ja) 2022-02-23 2025-04-10 ゼンコア インコーポレイテッド 抗ｃｄ２８×抗ｐｓｍａ抗体
WO2023227594A1 (en) 2022-05-24 2023-11-30 Gadeta Bv Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof
WO2023237541A1 (en) 2022-06-07 2023-12-14 Gadeta B.V. Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
WO2024013401A1 (en) 2022-07-15 2024-01-18 Gadeta B.V. Novel method for identifying gamma t-cell (or delta t-cell) receptor chains (or gammadelta t-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
AR129956A1 (es) 2022-07-18 2024-10-16 Ablynx Nv Compuestos de unión a cx3cr1, métodos y usos de los mismos
WO2024023271A1 (en) 2022-07-27 2024-02-01 Ablynx Nv Polypeptides binding to a specific epitope of the neonatal fc receptor
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2024096735A1 (en) 2022-10-31 2024-05-10 Stichting Amsterdam UMC Single domain anti-cd169 antibodies
WO2024101989A1 (en) 2022-11-08 2024-05-16 Stichting Amsterdam UMC Activation inducible antigen receptors for adoptive immunotherapy
EP4638472A1 (en) 2022-12-19 2025-10-29 UMC Utrecht Holding B.V. Btn2a1 binding peptide
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
JP2026506075A (ja) 2023-02-17 2026-02-20 アブリンクス エン．ヴェー． 新生児型ｆｃ受容体に結合するポリペプチド
WO2024251826A1 (en) 2023-06-05 2024-12-12 Vib Vzw Glyco-engineered antibody-drug-conjugates comprising an oxime linker
WO2024251981A1 (en) 2023-06-09 2024-12-12 Umc Utrecht Holding B.V. Detecting and/or modulating susceptibility to btn2a1 and/or btn3a1 targeting therapeutics
WO2025008537A1 (en) 2023-07-05 2025-01-09 Ablynx Nv Improved fcrn antagonists for treatment of igg-related diseases and disorders
GB202314424D0 (en) 2023-09-20 2023-11-01 Cambridge Entpr Ltd A conjugate
WO2025061919A1 (en) 2023-09-22 2025-03-27 Ablynx Nv Bi- and multivalent albumin binders
AR134267A1 (es) 2023-11-08 2025-12-17 Sanofi Sa Degradador lisosómico basado en cd25 y usos del mismo
TW202543670A (zh) 2023-12-22 2025-11-16 比利時商艾伯霖克斯公司 用於核內投予之基於蛋白質的接合載劑
US20250236673A1 (en) 2023-12-22 2025-07-24 Ablynx N.V. Protein-based carriers for site-specific amine conjugation
WO2025207946A1 (en) 2024-03-28 2025-10-02 Genzyme Corporation Polypeptides binding to a specific epitope of the transferrin receptor 1
WO2025262150A2 (en) 2024-06-18 2025-12-26 Ablynx Nv Antibody-recruiting molecules
WO2026029677A1 (en) 2024-08-02 2026-02-05 Erasmus University Medical Center Rotterdam Co-stimulatory t-cell receptor to treat patient with tumor or immune-related disease
WO2026052756A1 (en) 2024-09-05 2026-03-12 Ablynx Nv Her2 binding immunoglobulin single variable domains, constructs comprising the same and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
GB8927230D0 (en) * 1989-12-01 1990-01-31 Unilever Plc Reagents
ES2093778T3 (es) * 1991-04-26 1997-01-01 Surface Active Ltd Nuevos anticuerpos y metodos para su uso.
EP0584421A1 (en) * 1992-08-21 1994-03-02 Cécile Casterman Immunoglobulins devoid of light chains

Also Published As

Publication number Publication date
US20040253250A1 (en) 2004-12-16
NZ506453A (en) 2003-02-28
JP2003525016A (ja) 2003-08-26
HK1041210A1 (zh) 2002-07-05
US20020155604A1 (en) 2002-10-24
NO20004095L (no) 2000-10-18
EP1469883A2 (en) 2004-10-27
CA2321199A1 (en) 1999-08-26
US20050261478A1 (en) 2005-11-24
WO1999042077A3 (en) 2004-05-27
KR20010034512A (ko) 2001-04-25
CN1316910A (zh) 2001-10-10
NO20004095D0 (no) 2000-08-16
IL137963A0 (en) 2001-10-31
WO1999042077A2 (en) 1999-08-26
AU3295299A (en) 1999-09-06
BR9907950A (pt) 2001-12-18

Similar Documents

Publication Publication Date Title
ID26964A (id) Komposisi dan metode untuk pengaturan pengaktifan limfosit
ID29591A (id) Senyawa-senyawa kuinolina dan kuinoksalina
ID23575A (id) Pirazolopirimidina-pirazolopirimidina dan pirazolotriazina-pirazolotriazina
ID29013A (id) Ligan-ligan reseptor novel thiroid dan metode ii
ID28728A (id) Komposisi dan proses pengkrepan
ID24196A (id) Komposisi dan penggunaan
ID27667A (id) Komposisi coklat dan pemakaiannya
ID18354A (id) Metoda dan susunan untuk komunikasi radio
DE69941559D1 (de) Enzymgemisch
NO20002470L (no) Ny materialsammensetning
ID22431A (id) Komposisi surfaktan agrokimia
DE69703048D1 (de) Glaszusammensetzung, verfahren und verwendung
ID19422A (id) Piridina dan bifenil tersubstitusi
DE69939748D1 (de) Multipartikuläre zusammensetzung von methylphenidat mit modifizierter freisetzung
ID22009A (id) Metoda dan peralatan destilasi
PT1123441E (pt) Composicoes e metodos para preparar dispersoes e metodos para utilizar as dispersoes
ID28752A (id) Metode-metode dan komposisi-komposisi sanitasi
ID20303A (id) Komposisi surfaktan
ID29053A (id) Metode untuk menghasilkan 3-alkanoilindola dan 3-alkilindola
ID19803A (id) Komposisi zat warna rambut dan metoda pengentalannya
ID26028A (id) Komposisi penghambat polimerisasi, penghambat polimerisasi dan metode penghambatan polimerisasi
ID16889A (id) Senyawa turunan alkilaminobenzotiazol dan benzoksazol
DE69916503D1 (de) Poliermittelzusammensetzung und anwendungsverfahren
ID24872A (id) Komposisi pengawet berdasarkan senyawa donor formaldehide dan iodopropinil
ID29547A (id) Metoda dan komposisi untuk pencegahan dan pengobatan tuberkulosis